drugset
drugset / Trial / NCT03547141

Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers

NCT03547141 ↗

Phase 1 Completed 28 enrolled Medy-Tox
RandomizedParallel-groupDouble-blindBasic science

Summary

To determine the pharmacodynamic and safety of MBA-P01 in Healthy Male Volunteers

Timeline

Start
2018-04-16
Primary completion
2018-08-28
Completion
2018-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 1 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 5 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 15 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 30 iu Intramuscular
Subject MBA-P01 Protein / enzyme biologic 1 iu Intramuscular
Subject MBA-P01 Protein / enzyme biologic 5 iu Intramuscular
Subject MBA-P01 Protein / enzyme biologic 15 iu Intramuscular
Subject MBA-P01 Protein / enzyme biologic 30 iu Intramuscular

Indications

No indication recorded.